BioBlogger_

BioCryst Receives Fast-Track Status for Peramivir, But Does It Justify The Stock's Appreciation? (BCRX)

The market does have the potential to be significant; however, I argue that the current valuation not only reflects that potential but implies that that potential will be realized with certainty.